scholarly journals Suppression of MKL1 promotes adipocytic differentiation and reduces the proliferation of myxoid liposarcoma cells

2020 ◽  
Vol 20 (6) ◽  
pp. 1-1
Author(s):  
Yohei Kamikawa ◽  
Kento Yokota ◽  
Kosuke Oikawa ◽  
Fuyuki Sato ◽  
Yasuteru Muragaki
Keyword(s):  
Myxoid Liposarcoma ◽  
Adipocytic Differentiation

scholarly journals Clinical and Molecular Spectrum of Liposarcoma

2018 ◽  
Vol 36 (2) ◽  
pp. 151-159 ◽  
Author(s):  
Alex Thomas John Lee ◽  
Khin Thway ◽  
Paul H. Huang ◽  
Robin Lewis Jones
Keyword(s):  
Malignant Tumors ◽  
Treatment Options ◽  
Chromosomal Translocation ◽  
Myxoid Liposarcoma ◽  
Adipocytic Differentiation ◽  
Well Differentiated ◽  
Pharmaceutical Agents ◽  
Active Investigation ◽  
Treatment Sensitivity

Liposarcomas are rare malignant tumors of adipocytic differentiation. The classification of liposarcomas into four principal subtypes reflects the distinct clinical behavior, treatment sensitivity, and underlying biology encompassed by these diseases. Increasingly, clinical management decisions and the development of investigational therapeutics are informed by an improved understanding of subtype-specific molecular pathology. Well-differentiated liposarcoma is the most common subtype and is associated with indolent behavior, local recurrence, and insensitivity to radiotherapy and chemotherapy. Dedifferentiated liposarcoma represents focal progression of well-differentiated disease into a more aggressive, metastasizing, and fatal malignancy. Both of these subtypes are characterized by recurrent amplifications within chromosome 12, resulting in the overexpression of disease-driving genes that have been the focus of therapeutic targeting. Myxoid liposarcoma is characterized by a pathognomonic chromosomal translocation that results in an oncogenic fusion protein, whereas pleomorphic liposarcoma is a karyotypically complex and especially poor-prognosis subtype that accounts for less than 10% of liposarcoma diagnoses. A range of novel pharmaceutical agents that aim to target liposarcoma-specific biology are under active investigation and offer hope of adding to the limited available treatment options for recurrent or inoperable disease.

Mediastinal Myxoid Liposarcoma with Intrapericardial Involvement and Large Pericardial Effusion

2015 ◽  
Vol 18 (5) ◽  
pp. 192
Author(s):  
Santiago Adolfo Endara ◽  
Gerardo Augusto Davalos ◽  
Ana Lucia Vinueza ◽  
Nelson Montalvo ◽  
Patricia Graciela Duran ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Pericardial Effusion ◽  
English Language ◽  
Mediastinal Mass ◽  
Soft Tissue Sarcomas ◽  
Myxoid Liposarcoma ◽  
Large Pericardial Effusion ◽  
Adipocytic Differentiation ◽  
Mediastinal Liposarcoma ◽  
Uncommon Neoplasm

Liposarcoma is the name given to a group of soft tissue sarcomas (STSs) with adipocytic differentiation. As a group, liposarcomas are the second most common STSs in adults. In 1951 Kozonis et al published that in the English language only four cases of liposarcomas originating in the mediastinum had been described. Primary mediastinal liposarcoma is an uncommon neoplasm of intrathoracic origin. We present the case of a 47-year-old woman diagnosed with a large mediastinal mass with intrapericardial invasion and massive pericardial effusion; biopsies showed a mediastinal liposarcoma.

Abstract 1183: PPARgamma agonist promotes adipocytic differentiation and potentiates the activity of trabectedin in myxoid liposarcoma

2016 ◽  
Author(s):  
Ezia Bello ◽  
Roberta Frapolli ◽  
Simonetta Andrea Licandro ◽  
Silvia Brich ◽  
Laura Carrassa ◽  
...  
Keyword(s):  
Myxoid Liposarcoma ◽  
Adipocytic Differentiation

scholarly journals DIscBIO: A User-Friendly Pipeline for Biomarker Discovery in Single-Cell Transcriptomics

2021 ◽  
Vol 22 (3) ◽  
pp. 1399
Author(s):  
Salim Ghannoum ◽  
Waldir Leoncio Netto ◽  
Damiano Fantini ◽  
Benjamin Ragan-Kelley ◽  
Amirabbas Parizadeh ◽  
...  
Keyword(s):  
Single Cell ◽  
Biomarker Discovery ◽  
Enrichment Analysis ◽  
Myxoid Liposarcoma ◽  
R Package ◽  
Differential Analysis ◽  
A Cell ◽  
Reproducible Analysis ◽  
Transcriptomic Level ◽  
User Friendly

The growing attention toward the benefits of single-cell RNA sequencing (scRNA-seq) is leading to a myriad of computational packages for the analysis of different aspects of scRNA-seq data. For researchers without advanced programing skills, it is very challenging to combine several packages in order to perform the desired analysis in a simple and reproducible way. Here we present DIscBIO, an open-source, multi-algorithmic pipeline for easy, efficient and reproducible analysis of cellular sub-populations at the transcriptomic level. The pipeline integrates multiple scRNA-seq packages and allows biomarker discovery with decision trees and gene enrichment analysis in a network context using single-cell sequencing read counts through clustering and differential analysis. DIscBIO is freely available as an R package. It can be run either in command-line mode or through a user-friendly computational pipeline using Jupyter notebooks. We showcase all pipeline features using two scRNA-seq datasets. The first dataset consists of circulating tumor cells from patients with breast cancer. The second one is a cell cycle regulation dataset in myxoid liposarcoma. All analyses are available as notebooks that integrate in a sequential narrative R code with explanatory text and output data and images. R users can use the notebooks to understand the different steps of the pipeline and will guide them to explore their scRNA-seq data. We also provide a cloud version using Binder that allows the execution of the pipeline without the need of downloading R, Jupyter or any of the packages used by the pipeline. The cloud version can serve as a tutorial for training purposes, especially for those that are not R users or have limited programing skills. However, in order to do meaningful scRNA-seq analyses, all users will need to understand the implemented methods and their possible options and limitations.

scholarly journals The effects of locomotion on bone marrow mesenchymal stem cell fate: insight into mechanical regulation and bone formation

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yuanxiu Sun ◽  
Yu Yuan ◽  
Wei Wu ◽  
Le Lei ◽  
Lingli Zhang
Keyword(s):  
Bone Marrow ◽  
Cell Fate ◽  
Differentiation Potential ◽  
Stem Cell Fate ◽  
Proliferation And Differentiation ◽  
Marrow Mesenchymal Stem Cells ◽  
Adipocytic Differentiation ◽  
Regulatory Effects ◽  
Insight Into ◽  
Mechanical Regulation

AbstractBone marrow mesenchymal stem cells (BMSCs) refer to a heterogeneous population of cells with the capacity for self-renewal. BMSCs have multi-directional differentiation potential and can differentiate into chondrocytes, osteoblasts, and adipocytes under specific microenvironment or mechanical regulation. The activities of BMSCs are closely related to bone quality. Previous studies have shown that BMSCs and their lineage-differentiated progeny (for example, osteoblasts), and osteocytes are mechanosensitive in bone. Thus, a goal of this review is to discuss how these ubiquious signals arising from mechanical stimulation are perceived by BMSCs and then how the cells respond to them. Studies in recent years reported a significant effect of locomotion on the migration, proliferation and differentiation of BMSCs, thus, contributing to our bone mass. This regulation is realized by the various intersecting signaling pathways including RhoA/Rock, IFG, BMP and Wnt signalling. The mechanoresponse of BMSCs also provides guidance for maintaining bone health by taking appropriate exercises. This review will summarize the regulatory effects of locomotion/mechanical loading on BMSCs activities. Besides, a number of signalling pathways govern MSC fate towards osteogenic or adipocytic differentiation will be discussed. The understanding of mechanoresponse of BMSCs makes the foundation for translational medicine.

scholarly journals Carbon ion radiotherapy for recurrent calf myxoid liposarcoma: a case report

2021 ◽  
Vol 49 (4) ◽  
pp. 030006052110097
Author(s):  
Xiaojun Li ◽  
Yanshan Zhang ◽  
Yancheng Ye ◽  
Ying Qi ◽  
Chunlan Feng ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Myxoid Liposarcoma ◽  
Ion Beams ◽  
Carbon Ion Radiotherapy ◽  
Irradiation Damage ◽  
Radiation Dermatitis ◽  
Complete Disappearance ◽  
Carbon Ion ◽  
The Right

Liposarcoma (LPS) is the most common soft tissue sarcoma. Myxoid LPS (MLPS) is the second most common subtype of LPS and accounts for 25% to 50% of all LPSs. Like most other soft tissue sarcomas, the mainstay of treatment for LPS is inevitably surgery. Multidisciplinary approaches, including surgery, chemotherapy, and radiotherapy, have been successful in the treatment of LPS during the last three decades. Even so, recurrence of LPS remains challenging. Carbon ion beams produce increased energy deposition at the end of their range to form a Bragg peak while minimizing irradiation damage to surrounding tissues, which facilitates more precise dosage and localization than that achieved with photon beams. Furthermore, carbon ion beams have high relative biologic effectiveness. We herein describe a patient who developed recurrent MLPS in the right calf after two surgeries and underwent carbon ion radiotherapy (CIRT), achieving complete disappearance of the tumor. The patient developed Grade 1 radiation dermatitis 30 days after CIRT, but no other acute toxicities were observed. The tumor had completely disappeared by 120 days after CIRT, and the patient remained disease-free for 27 months after CIRT. The CARE guidelines were followed in the reporting of this case.

DDIT3 immunohistochemistry is highly sensitive for the diagnosis of myxoid liposarcoma but care is required in interpreting the significance of focal expression

2021 ◽  
Author(s):  
Ana Cristina Vargas ◽  
Noni L Chan ◽  
Daniel D Wong ◽  
Matthew Zabarowski ◽  
Talia L Fuchs ◽  
...  
Keyword(s):  
Myxoid Liposarcoma ◽  
Highly Sensitive ◽  
Focal Expression
Sign in / Sign up

Export Citation Format

Share Document